Edward K Schaeffer

US Patent:

20140073527, Mar 13, 2014

Filed:

Sep 10, 2013

Appl. No.:

14/022468

Inventors:

Edward M. Schaeffer - Sparks MD, US

Assignee:

THE JOHNS HOPKINS UNIVERSITY - BALTIMORE MD

International Classification:

C12Q 1/68
G01N 33/574

US Classification:

506 9, 435 612, 436501, 435 71

Abstract:

The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for assessing prostate cancer in a patient. In a specific embodiment, a method for determining a likelihood of prostate cancer recurrence in a patient following prostectomy comprises the steps of (a) obtaining a biological sample from the patient; (b) subjecting the sample to an assay for detecting SPARCL1 expression; and (c) determining that prostate cancer is likely to recur if SPARCL1 expression is decreased relative to a reference non-prostate cancer sample.

US Patent:

20170016903, Jan 19, 2017

Filed:

Mar 2, 2015

Appl. No.:

15/121783

Inventors:

- Baltimore MD, US
Edward M. SCHAEFFER - Sparks MD, US
Luigi MARCHIONNI - Baltimore MD, US

International Classification:

G01N 33/574

Abstract:

The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for identification of individuals having clinically significant cancer. In one embodiment, a method for treating a subject having prostate cancer comprises the steps of (a) obtaining a biological sample from the subject; (b) performing an assay on the sample obtained from the subject to measure the levels of one or more protein biomarkers listed in Table 1; (c) comparing the measured levels of one or more protein biomarkers to one or more reference controls to identify the subject as having high grade prostate cancer, low grade prostate cancer or no prostate cancer; and (d) treating the subject with one or more treatment modalities appropriate for a subject having high grade prostate cancer or low grade prostate cancer.

US Patent:

20160130662, May 12, 2016

Filed:

Jun 17, 2014

Appl. No.:

14/899352

Inventors:

- Baltimore MD, US
Edward M. SCHAEFFER - Sparks MD, US

International Classification:

C12Q 1/68

Abstract:

The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for assessing prostate cancer in a patient. In a specific embodiment, a method for predicting metastasis in a prostate cancer patient comprises the steps of (a) genotyping the ASPN D repeat domain length in both alleles of the patient using a polymerase chain reaction; (b) predicting metastasis in the patient if the ASPND repeat domain length is 13 in one allele and 14 in the other allele or have at least one allele with 14 D repeats as compared to other common allelic genotypes; and (c) predicting no metastasis in the patient if the ASPN D repeat domain length is 13 in both alleles as compared to other allelic genotypes.

US Patent:

20150299807, Oct 22, 2015

Filed:

Nov 21, 2013

Appl. No.:

14/646427

Inventors:

- Baltimore MD, US
Edward M. SCHAEFFER - Sparks MD, US

International Classification:

C12Q 1/68
A61B 5/15
A61B 10/00
G01N 33/574

Abstract:

The present invention relates to the field of biomarkers. More specifically, the present invention provides methods and compositions useful for diagnosing and/or prognosing prostate cancer. In a specific embodiment, a method for diagnosing prostate cancer or a likelihood thereof in a patient comprising the steps of (a) obtaining a biological sample from the patient; (b) subjecting the sample to an assay for detecting expression of one or more of ACSM2A, BDH2, C19orf51, C8orf76, CGB5, CSMD3, DAZ2, DUX4, FAM22G, FAM90A1, GABBR2, GRM3, HMMR, HOXC4, KAAG1, KRIT1, KRTAP20-1, LOC392196, LOC441956, LOC650293, LTB4R, METTL7B, NEK2, OR11H12, OR2J3, OR2L8, OR2M1P, OR2T3, OR4F5, OR52A4, OR5211, PGA3, PHACTR3, PMP2, PRAMEF6, PSG1, SIGLEC10, SOX11, SPDYE1, SSX1, TCEB3B, TCFL5, TFAP2D, TSPY2, UGT2B10, UGT2B11, UGT2B28, WDR49, and WFDC5; and (c) determining that the patient has prostate cancer or a likelihood thereof if the expression of the one or more biomarkers is increased relative to a reference non-prostate cancer sample.